Givinostat
Small molecule
Evidence outlook
Approved: Duchenne Muscular Dystrophy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Polycythemia Vera · Phase 3 · investigational in the US
Also approved (2)
- Duvyzat is indicated for the treatment of Duchenne muscular dystrophy (DMD) in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment.
- Duchenne muscular dystrophy in patients aged 6 years and older, all genetic variants
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02851797 NCT02851797 · Duchenne Muscular Dystrophy The trial randomly assigned 179 participants to quadruple-blinded givinostat or placebo, with 81 and 39 participants, respectively, included in the primary target-population analysis. The hard clinical functional endpoint was met: the four-stair climb comparison favored givinostat with a ratio of 0.86 and p=0.0345. Registry: NCT02851797 | 3 | Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months) 2022-02-22 | Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other HDAC drugs
Romidepsin, Vorinostat, Panobinostat, Chidamide, Purinostat Mesylate. Compare all 6 HDAC drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Duchenne Muscular Dystrophy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Givinostat: this drug | Approved | Small molecule | HDAC | Reliable signal | NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | |
| Romidepsin | Approved(overall) | Small molecule | HDAC | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vorinostat | Approved(overall) | Small molecule | HDAC | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Panobinostat | US approval withdrawn(overall) | Small molecule | HDAC | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3(overall) | Small molecule | HDAC | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Deramiocel | Phase 3 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Purinostat Mesylate | Phase 3(overall) | Small molecule | HDAC | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RGX-202 | Phase 2/3 | Gene therapy / editing | Dystrophin (microdystrophin transgene) | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Zotadirsen | Phase 2 | RNA / oligonucleotide | DMD exon 44 | not yet graded | No reviewed efficacy summary in this indication | |
| Bampidirsen | Phase 1/2 | RNA / oligonucleotide | DMD exon 53 | not yet graded | No reviewed efficacy summary in this indication | |
| Nivudirsen (BMN 351) | Phase 1/2 | RNA / oligonucleotide | DMD exon 51 | not yet graded | No reviewed efficacy summary in this indication | |
| REC-2282 | Discontinued | Small molecule | HDAC | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Givinostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.